
Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Frank Sciurba, MD, professor of medicine at the University of Pittsburgh School of Medicine.

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

The phase 3 trials enrolled frequent exacerbators regardless of eosinophil count or smoking status.

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.